This year's Acarbose Cardiovascular Evaluation (ACE) Regional Investigator Meetings were held between 14th and 21st July in six Chinese cities: Beijing, Chengdu, Hangzhou, Guangzhou, Qingdao and Wuhan. We were thrilled by the high attendance, excellent interaction and the interest in the trial shown by Chinese clinicians. Over 300 ACE Investigators and other cardiologists joined us to hear presentations given by the ACE Steering Committee Members and representatives of some of the top performing sites.
Each meeting was opened by a Regional Key Opinion Leader under the lead of Prof. Pan Changyu and Prof. Hu Dayi and was followed by presentations by two of the International Key Opinion Leaders, all of whom are members of the ACE Steering Committee. They included Prof. Rury Holman, Prof. Hu Dayi, Prof. Jean Louis Chiasson, Prof. Hertzel Gerstein, Prof. Michal Tendera and Prof. Jaakko Tuomilehto. They all spoke of the importance of the ACE trial both in China and Internationally. China has enormous potential to become a major force in clinical trials, and the successful completion of the ACE study will be a significant step on the path to fulfilling that potential. ACE is also the first large clinical trial conducted solely in Chinese patients and the results may have a global impact on the treatment of impaired glucose tolerance.
In each region, three local Principal Investigators from the best performing sites were invited to share their experience on conducting the ACE Trial at their hospital. After the presentations, the participating Investigators took this opportunity to carry a discussion on the study, exchanging their questions and opinions. Three of the best recruiting sites of each region received rewards from the ACE Steering Committee Members.